Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Nov 14;14(1):413.
doi: 10.1186/s13104-021-05832-0.

Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru

Alvaro Schwalb  1 , Rodrigo Cachay  2 , Ericka Meza  2 , Tatiana Cáceres  2 , Amondrea Blackman  3 , Fernanda Maruri  3 , Timothy R Sterling  3 , Eduardo Gotuzzo  2
Affiliations

Fluoroquinolone susceptibility in first-line drug-susceptible M. tuberculosis isolates in Lima, Peru

Alvaro Schwalb et al. BMC Res Notes. .

Abstract

Objective: To determine at two distinct time points the prevalence of resistance to ofloxacin (OFX), the representative class drug of fluoroquinolones (FQs), in M. tuberculosis isolates susceptible to first-line drugs.

Results: There were 279 M. tuberculosis isolates from the two cohorts (2004-2005: 238 isolates; 2017: 41 isolates) that underwent OFX drug-susceptibility testing (critical concentration: 2 µg/ml). Of 238 isolates in Cohort 1, no resistance to OFX was detected (95% CI 0-0.016); likewise, in Cohort 2, no resistance to OFX was detected in 41 isolates (95% CI 0-0.086). Our findings suggest that FQ use remains a viable option for the treatment of first-line drug-susceptible TB in Peru.

Keywords: Drug resistance; Levofloxacin; Moxifloxacin; Ofloxacin.

PubMed Disclaimer

Conflict of interest statement

The authors have no relevant financial or non-financial interests to disclose.

References

    1. Drlica K, Malik M. Fluoroquinolones: action and resistance. Curr Top Med Chem. 2003;3:249–282. doi: 10.2174/1568026033452537. - DOI - PubMed
    1. Sterling TR. Fluoroquinolones for the treatment and prevention of multidrug-resistant tuberculosis. Int J Tuberc Lung Dis. 2016;20:42–47. doi: 10.5588/ijtld.16.0117. - DOI - PubMed
    1. World Health Organization . Consolidated guidelines on drug-resistant tuberculosis treatment. Geneva: World Health Organization; 2019. - PubMed
    1. Nahid P, Dorman SE, Alipanah N, Barry PM, Brozek JL, Cattamanchi A, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016;63:e147–e195. doi: 10.1093/cid/ciw376. - DOI - PMC - PubMed
    1. Dorman SE, Nahid P, Kurbatova EV, Phillips PPJ, Bryant K, Dooley KE, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med. 2021;384:1705–1718. doi: 10.1056/NEJMoa2033400. - DOI - PMC - PubMed

MeSH terms